3PC-062 Impact of the preparation of 1.0 mg/mL nivolumab clinical solution on the particulates (aggregation) measured by dynamic light scattering: NaCl and glucose concentration and agitation effect

Background and importanceNivolumab (Opdivo) is a human immunoglobulin G4 monoclonal antibody that binds to programmed death receptor 1 (PD-1) and blocks its interaction with PD-L1 and PD-L2. As a complex protein, routine handling or unintentional mishandling of its solutions may cause degradation th...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of hospital pharmacy. Science and practice 2021-03, Vol.28 (Suppl 1), p.A18-A18
Hauptverfasser:	Torrente-López, A, Hermosilla Fernández, J, Muñoz-Prieto, D, Hernández-Jiménez, J, Cabeza, J, Navas, N, Salmerón-García, A
Format:	Artikel
Sprache:	eng
Schlagworte:	Conflicts of interest Glucose Immunotherapy Monoclonal antibodies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!